{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:00:51Z","timestamp":1793066451104,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T00:00:00Z","timestamp":1491436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijantimicag.2017.01.010","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:36:41Z","timestamp":1490747801000},"page":"579-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia"],"prefix":"10.1016","volume":"49","author":[{"given":"Xinyu","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Giang","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ja","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-6335","authenticated-orcid":false,"given":"Dung Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Laud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-5877","authenticated-orcid":false,"given":"Joseph W.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0010","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0015","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1128\/AAC.00971-12","volume":"57","author":"Sheng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0020","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/cc8892","article-title":"Bench-to-bedside review: the role of \u03b2-lactamases in antibiotic-resistant Gram-negative infections","volume":"14","author":"Bush","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0025","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1749-7922-8-3","article-title":"2013 WSES guidelines for management of intra-abdominal infections","volume":"8","author":"Sartelli","year":"2013","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0030","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0035","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1093\/cid\/cit128","article-title":"Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections","volume":"56","author":"Solomkin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0040","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0045","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jac\/dkw398","volume":"72","author":"Jean","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0050","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0055","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0060","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1128\/AAC.01722-10","article-title":"Activity of NXL104 in combination with \u03b2-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum \u03b2-lactamases and class C \u03b2-lactamases","volume":"55","author":"Lagace-Wiens","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0065","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Aktas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0070","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime\u2013avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0075","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/AAC.03267-14","article-title":"In vivo efficacy of humanized exposures of ceftazidime\u2013avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates","volume":"58","author":"MacVane","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0080","author":"Actavis Inc."},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0085","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0090","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0095","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime\u2013avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection\u2014results from a randomised, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0100","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0105","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Results from REPRISE, a randomised, pathogen-directed phase 3 study of ceftazidime\u2013avibactam or best available therapy in patients with ceftazidime-resistant complicated urinary tract infections or complicated intra-abdominal infections","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0110","author":"AstraZeneca Ltd"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0115","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2174\/1389200215666140605130935","article-title":"A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?","volume":"15","author":"Baietto","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0120","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0125","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0130","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0135","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0140","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/sur.2011.048","article-title":"Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial","volume":"13","author":"Qvist","year":"2012","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0145","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0150","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijantimicag.2009.06.022","article-title":"Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections","volume":"34","author":"Solomkin","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0155","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-015-0347-x","article-title":"A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime\u2013avibactam in healthy Chinese subjects","volume":"36","author":"Li","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0160","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jiac.2015.04.006","article-title":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime\u2013avibactam in healthy Japanese volunteers","volume":"21","author":"Tominaga","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0165","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane\u2013tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.010_bib0170","author":"GlaxoSmithKline"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T05:19:18Z","timestamp":1568956758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924857917300961"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}